- Supernus Pharmaceuticals (NASDAQ:SUPN -1.8%) Q2 results: Revenues: $29.7M (+999%); Operating Income: $3.8M (+124.3%); Net Income: $3.2M (+111.7%); EPS: $0.08 (+109.0%); Quick Assets: $47.3M (-42.5%).
- 2014 Guidance: Revenue: ~$105M; cash burn: $5M - 10M; quick assets at year end: $75M - 85M; net income: >$0.
- 2015 Guidance: Cash flow positive.
Supernus Pharma ups revenue guidance after Q2 results
Recommended For You
More Trending News
About SUPN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SUPN | - | - |
Supernus Pharmaceuticals, Inc. |